Advertisement
Screener

ONKURE THERAPEUTICS, INC. (OKUR) Investing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

ONKURE THERAPEUTICS, INC. Investing Cash Flow

ONKURE THERAPEUTICS, INC. (OKUR) reported Investing Cash Flow of -$9.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-04

  • ONKURE THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$9.87M.
  • ONKURE THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$5.00K.
  • ONKURE THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$9.00K, a 100.06% decline year-over-year.
  • ONKURE THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$6.00K.
  • ONKURE THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$46.00K, a 100.29% decline from fiscal 2024.
  • ONKURE THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2024 was $15.87M.
  • ONKURE THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2023 was -$246.00K.
  • ONKURE THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2022 was -$57.84M.
Period endNet Cash Provided by (Used in) Investing Activities 3 monthNet Cash Provided by (Used in) Investing Activities 3 month as first filedNet Cash Provided by (Used in) Investing Activities 6 monthNet Cash Provided by (Used in) Investing Activities 6 month as first filedNet Cash Provided by (Used in) Investing Activities 9 monthNet Cash Provided by (Used in) Investing Activities 9 month as first filedNet Cash Provided by (Used in) Investing Activities 12 monthNet Cash Provided by (Used in) Investing Activities 12 month as first filed
2026-06-30-$9.87M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
-$9.88M
10-Q · filed 2026-08-04
-$9.88M
derived: sum of 3 quarters · filed 2026-08-04
-$9.89M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31-$5.00K
10-Q · filed 2026-05-05
-$14.00K
derived: sum of 2 quarters · filed 2026-05-05
-$20.00K
derived: sum of 3 quarters · filed 2026-05-05
-$33.00K
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31-$9.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
-$15.00K
derived: sum of 2 quarters · filed 2026-03-12
-$28.00K
derived: sum of 3 quarters · filed 2026-08-04
-$46.00K
10-K · filed 2026-03-12
2025-09-30-$6.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$19.00K
derived: sum of 2 quarters · filed 2026-08-04
-$37.00K
10-Q · filed 2025-11-06
$15.87M
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30-$13.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
-$31.00K
10-Q · filed 2026-08-04
$15.88M
derived: sum of 3 quarters · filed 2026-08-04
$15.86M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31-$18.00K
10-Q · filed 2026-05-05
$15.89M
derived: sum of 2 quarters · filed 2026-05-05
$15.87M
derived: sum of 3 quarters · filed 2026-05-05
$15.86M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31$15.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$15.89M
derived: sum of 2 quarters · filed 2026-03-12
$15.88M
derived: sum of 3 quarters · filed 2026-03-12
$15.87M
10-K · filed 2026-03-12
2024-09-30-$18.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$28.00K
derived: sum of 2 quarters · filed 2025-11-06
-$37.00K
10-Q · filed 2025-11-06
$61.25M
10-Q · filed 2024-11-07
$28.97M
derived: sum of 4 quarters · filed 2025-11-06
2024-06-30-$10.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
-$19.00K
10-Q · filed 2025-08-12
$36.25M
10-Q · filed 2024-08-13
$28.99M
derived: sum of 3 quarters · filed 2025-08-12
$50.24M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31-$9.00K
10-Q · filed 2025-05-06
$13.76M
10-Q · filed 2024-05-07
$29.00M
derived: sum of 2 quarters · filed 2025-05-06
$50.25M
derived: sum of 3 quarters · filed 2025-05-06
-$18.76M
derived: sum of 4 quarters · filed 2025-05-06
2023-12-31$29.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10
$50.26M
derived: sum of 2 quarters · filed 2025-03-10
-$18.75M
derived: sum of 3 quarters · filed 2025-03-10
-$246.00K
10-K · filed 2025-03-10
$10.52M
10-K · filed 2024-03-28
2023-09-30$21.25M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
-$47.76M
derived: sum of 2 quarters · filed 2024-11-07
-$29.25M
10-Q · filed 2024-11-07
-$56.17M
derived: sum of 4 quarters · filed 2024-11-07
2023-06-30-$69.01M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
-$50.50M
10-Q · filed 2024-08-13
-$77.42M
derived: sum of 3 quarters · filed 2024-08-13
-$122.86M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31$18.51M
10-Q · filed 2024-05-07
-$8.41M
derived: sum of 2 quarters · filed 2024-05-07
-$53.84M
derived: sum of 3 quarters · filed 2024-05-07
-$44.76M
derived: sum of 4 quarters · filed 2024-05-07
2022-12-31-$26.92M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28
-$72.35M
derived: sum of 2 quarters · filed 2024-03-28
-$63.27M
derived: sum of 3 quarters · filed 2024-03-28
-$57.84M
10-K · filed 2024-03-28
2022-09-30-$45.44M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
-$36.35M
derived: sum of 2 quarters · filed 2023-11-13
-$30.93M
10-Q · filed 2023-11-13
-$22.77M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30$9.08M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
$14.51M
10-Q · filed 2023-08-10
$22.66M
derived: sum of 3 quarters · filed 2023-08-10
$18.15M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31$5.43M
10-Q · filed 2023-05-11
$13.58M
derived: sum of 2 quarters · filed 2023-05-11
$9.07M
derived: sum of 3 quarters · filed 2023-05-11
-$17.92M
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31$8.15M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27
$3.64M
derived: sum of 2 quarters · filed 2023-03-27
-$23.35M
derived: sum of 3 quarters · filed 2023-03-27
-$23.38M
10-K · filed 2023-03-27
2021-09-30-$4.51M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
-$31.50M
derived: sum of 2 quarters · filed 2022-11-08
-$31.53M
10-Q · filed 2022-11-08
-$31.55M
derived: sum of 4 quarters · filed 2022-11-08
2021-06-30-$27.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
-$27.02M
10-Q · filed 2022-08-09
-$27.04M
derived: sum of 3 quarters · filed 2022-08-09
-$25.84M
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31-$25.00K
10-Q · filed 2022-05-10
-$41.00K
derived: sum of 2 quarters · filed 2022-05-10
$1.15M
derived: sum of 3 quarters · filed 2022-05-10
$2.15M
derived: sum of 4 quarters · filed 2022-05-10
2020-12-31-$16.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23
$1.18M
derived: sum of 2 quarters · filed 2022-03-23
$2.18M
derived: sum of 3 quarters · filed 2022-03-23
$7.38M
10-K · filed 2022-03-23
2020-09-30$1.19M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12
$2.19M
derived: sum of 2 quarters · filed 2021-11-12
$7.39M
10-Q · filed 2021-11-12
2020-06-30$1.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11
$6.20M
10-Q · filed 2021-08-11
2020-03-31$5.20M
10-Q · filed 2021-05-20

Similar stocks

Stock NameCountryMarket CapPE Ratio
Coya Therapeutics, Inc. (COYA)United States$0.121B-6.35
CUMBERLAND PHARMACEUTICALS INC (CPIX)United States$0.121B-8.95
Aardvark Therapeutics, Inc. (AARD)United States$0.121B-1.80
Immuneering Corp (IMRX)United States$0.113B-12.51
Quantum Cyber N.V. (QUCY)$0.113B
INOVIO PHARMACEUTICALS, INC. (INO)United States$0.125B-1.35
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
IMMUNIC, INC. (IMUX)United States$0.127B-1.88
GENELUX Corp (GNLX)United States$0.110B-3.83
Equillium, Inc. (EQ)United States$0.109B-11.27